182 related articles for article (PubMed ID: 20053750)
1. N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site.
Mishin VP; Watanabe M; Taylor G; Devincenzo J; Bose M; Portner A; Alymova IV
J Virol; 2010 Mar; 84(6):3094-100. PubMed ID: 20053750
[TBL] [Abstract][Full Text] [Related]
2. Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.
Alymova IV; Taylor G; Mishin VP; Watanabe M; Murti KG; Boyd K; Chand P; Babu YS; Portner A
J Virol; 2008 Sep; 82(17):8400-10. PubMed ID: 18579600
[TBL] [Abstract][Full Text] [Related]
3. Mutation at residue 523 creates a second receptor binding site on human parainfluenza virus type 1 hemagglutinin-neuraminidase protein.
Bousse T; Takimoto T
J Virol; 2006 Sep; 80(18):9009-16. PubMed ID: 16940513
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of parainfluenza virus type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: effect of receptor avidity and steric hindrance at the inhibitor binding sites.
Porotto M; Murrell M; Greengard O; Lawrence MC; McKimm-Breschkin JL; Moscona A
J Virol; 2004 Dec; 78(24):13911-9. PubMed ID: 15564499
[TBL] [Abstract][Full Text] [Related]
5. A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism.
Porotto M; Fornabaio M; Kellogg GE; Moscona A
J Virol; 2007 Apr; 81(7):3216-28. PubMed ID: 17229690
[TBL] [Abstract][Full Text] [Related]
6. Glycosylation of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 1 affects its functional but not its antigenic properties.
Gorman WL; Pridgen C; Portner A
Virology; 1991 Jul; 183(1):83-90. PubMed ID: 1647078
[TBL] [Abstract][Full Text] [Related]
7. Role of N-linked glycosylation of the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein.
Chu FL; Wen HL; Hou GH; Lin B; Zhang WQ; Song YY; Ren GJ; Sun CX; Li ZM; Wang Z
Virus Res; 2013 Jun; 174(1-2):137-47. PubMed ID: 23562646
[TBL] [Abstract][Full Text] [Related]
8. Fixation of oligosaccharides to a surface may increase the susceptibility to human parainfluenza virus 1, 2, or 3 hemagglutinin-neuraminidase.
Tappert MM; Smith DF; Air GM
J Virol; 2011 Dec; 85(23):12146-59. PubMed ID: 21917945
[TBL] [Abstract][Full Text] [Related]
9. Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.
Alymova IV; Portner A; Mishin VP; McCullers JA; Freiden P; Taylor GL
Glycobiology; 2012 Feb; 22(2):174-80. PubMed ID: 21846691
[TBL] [Abstract][Full Text] [Related]
10. [Study on functions of N-carbohydrate chains in human parainfluenza virus type 3 hemagglutinin-neuraminidase protein].
Chu FL; Wen HL; Hou GH; Lin B; Zhang WQ; Song YY; Ren GJ; Sun CX; Li ZM; Wang ZY
Bing Du Xue Bao; 2013 Sep; 29(5):500-8. PubMed ID: 24386838
[TBL] [Abstract][Full Text] [Related]
11. Structural Insights into Human Parainfluenza Virus 3 Hemagglutinin-Neuraminidase Using Unsaturated 3- N-Substituted Sialic Acids as Probes.
Pascolutti M; Dirr L; Guillon P; Van Den Bergh A; Ve T; Thomson RJ; von Itzstein M
ACS Chem Biol; 2018 Jun; 13(6):1544-1550. PubMed ID: 29693380
[TBL] [Abstract][Full Text] [Related]
12. Targeting Human Parainfluenza Virus Type-1 Haemagglutinin-Neuraminidase with Mechanism-Based Inhibitors.
Eveno T; Dirr L; El-Deeb IM; Guillon P; von Itzstein M
Viruses; 2019 May; 11(5):. PubMed ID: 31060278
[TBL] [Abstract][Full Text] [Related]
13. Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III.
Lawrence MC; Borg NA; Streltsov VA; Pilling PA; Epa VC; Varghese JN; McKimm-Breschkin JL; Colman PM
J Mol Biol; 2004 Jan; 335(5):1343-57. PubMed ID: 14729348
[TBL] [Abstract][Full Text] [Related]
14. New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase.
Chibanga VP; Dirr L; Guillon P; El-Deeb IM; Bailly B; Thomson RJ; von Itzstein M
Antiviral Res; 2019 Jul; 167():89-97. PubMed ID: 30951732
[TBL] [Abstract][Full Text] [Related]
15. Exposing the flexibility of human parainfluenza virus hemagglutinin-neuraminidase.
Winger M; von Itzstein M
J Am Chem Soc; 2012 Nov; 134(44):18447-52. PubMed ID: 23057491
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.
Alymova IV; Taylor G; Takimoto T; Lin TH; Chand P; Babu YS; Li C; Xiong X; Portner A
Antimicrob Agents Chemother; 2004 May; 48(5):1495-502. PubMed ID: 15105096
[TBL] [Abstract][Full Text] [Related]
17. An oligosaccharide at the C-terminus of the F-specific domain in the stalk of the human parainfluenza virus 3 hemagglutinin-neuraminidase modulates fusion.
Wang Z; Mirza AM; Li J; Mahon PJ; Iorio RM
Virus Res; 2004 Feb; 99(2):177-85. PubMed ID: 14749183
[TBL] [Abstract][Full Text] [Related]
18. Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN).
Streltsov VA; Pilling P; Barrett S; McKimm-Breschkin JL
Antiviral Res; 2015 Nov; 123():216-23. PubMed ID: 26364554
[TBL] [Abstract][Full Text] [Related]
19. A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.
Murrell MT; Porotto M; Greengard O; Poltoratskaia N; Moscona A
J Virol; 2001 Jul; 75(14):6310-20. PubMed ID: 11413297
[TBL] [Abstract][Full Text] [Related]
20. The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity.
Gorman WL; Gill DS; Scroggs RA; Portner A
Virology; 1990 Mar; 175(1):211-21. PubMed ID: 1689918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
